DIVISLAB — Divis Laboratories Balance Sheet
0.000.00%
- IN₹1.76tn
- IN₹1.75tn
- IN₹93.60bn
Annual balance sheet for Divis Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 20,303 | 12,148 | 1,697 | 3,630 | 4,150 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 18,198 | 25,896 | 20,372 | 23,950 | 30,060 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 61,747 | 83,515 | 93,117 | 96,750 | 100,810 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 44,095 | 47,875 | 49,292 | 55,130 | 64,600 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 107,741 | 133,747 | 144,388 | 154,700 | 169,320 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11,125 | 11,956 | 11,011 | 12,780 | 14,520 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 14,795 | 16,465 | 16,717 | 18,990 | 19,630 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 92,946 | 117,282 | 127,671 | 135,710 | 149,690 |
| Total Liabilities & Shareholders' Equity | 107,741 | 133,747 | 144,388 | 154,700 | 169,320 |
| Total Common Shares Outstanding |